Study of the efficacy of Mokuboito in patients with acute decompensated heart failure.

Study of the efficacy of Mokuboito in patients with acute decompensated heart failure. - The efficacy of Mokuboito in patients with ADHF.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026621

Enrollment

Registered

2017-03-23

Start date

2017-03-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute decompensated heart failure(ADHF)

Interventions

Additional administration of Mokuboito 7.5g/day on standard therapy for ADHF. Standard therapy for ADHF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who need admission due to ADHF 2) Patients who gave written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients younger than 20 years old 2) Patients who cannot make oral communication due to shock state or intubation 3) Patients who are pregnant or hope to be pregnant 4) Patients who cannot take oral administration 5) Patients who have allergy for cinnamon 6) Patients who cannot undergo proper medical examination or body weight measurement due to orthopnea 7) Patients whose doctor in charge do not agree to join the trial

Design outcomes

Primary

Measure	Time frame
The changes in global clinical status based on a visual analog scale and body weight at day 10 or discharge if earlier.	—

Secondary

Measure	Time frame
The change of plasma brain natriuretic peptide concentration, parameters measured using echocardiography, and the degree of peripheral edema at day 10 or discharge if earlier.	—

Countries

Japan

Contacts

Public ContactHirotaka Ezaki

Tokorozawa Heart Center Department of Cardiology

hirotakaezaki@gmail.com04-2940-8611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026